NKCFO LLC’s Haemonetics HAE Stock Holding History

NKCFO LLC’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,150	Closed	-$315K	–	113
2018 Q4	$315K	Buy	+3,150	New	+$331K	0.24%	32

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

NKCFO LLC's HAE Position: Q1 2019 in Review

NKCFO LLC sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 3,150 shares — an estimated $315K sold.

NKCFO LLC first reported a position in HAE in Q4 2018 and held it in 1 quarter. The position peaked at $315K in Q4 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

NKCFO LLC reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
NKCFO LLC sold 3,150 Haemonetics shares in Q1 2019, an estimated $315K.
NKCFO LLC first reported a position in Haemonetics in Q4 2018 and held it in 1 quarter.
NKCFO LLC's Haemonetics position peaked at $315K in Q4 2018.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on NKCFO LLC's 13F filing for Q1 2019, filed 18 Apr 2019.